Zymeworks stock rises 5.5% on $813M Roche licensing deal
FROM THE WIRE · FINANCE.YAHOO.COM
Investing.com -- Zymeworks Inc (NASDAQ:ZYME) shares rose 5.5% in premarket trading Friday following the announcement of a global license and collaboration agreement with Roche for ZW209, a T cell engager targeting DLL3, in a deal worth up to $813 million. Still guessing which…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA licensing deal with a large pharma partner can re-rate a mid-cap biotech stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Zymeworks announced a global license and collaboration agreement with Roche for ZW209.
- 02The deal is worth up to $813 million, including a $55 million upfront payment.
- 03The company is eligible for up to $718 million in additional milestone payments plus royalties.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets